Actuate Therapeutics, Inc. (ACTU)

Actuate Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	8.64	2.96	20.45
Cash & Short-Term Investments	8.64	2.96	20.45
Cash Growth	192.08%	-85.53%	-
Prepaid Expenses	0.57	0.04	0.03
Total Current Assets	9.21	3	20.48
Other Long-Term Assets	0.11	-	-
Total Assets	9.32	3	20.48
Accounts Payable	1.92	3.42	2.13
Accrued Expenses	6.88	3.5	2.21
Total Current Liabilities	8.8	6.92	4.34
Other Long-Term Liabilities	0.41	0.54	0.49
Total Liabilities	9.21	7.46	4.84
Common Stock	0	0	0
Additional Paid-In Capital	132.48	5.47	5.04
Retained Earnings	-132.38	-105.09	-80.35
Total Common Equity	0.1	-99.63	-75.31
Shareholders' Equity	0.1	-4.46	15.65
Total Liabilities & Equity	9.32	3	20.48
Net Cash (Debt)	8.64	2.96	20.45
Net Cash Growth	192.08%	-85.53%	-
Net Cash Per Share	1.03	2.06	16.89
Filing Date Shares Outstanding	19.53	1.69	1.21
Total Common Shares Outstanding	19.53	1.69	1.21
Working Capital	0.41	-3.93	16.14
Book Value Per Share	0.01	-58.93	-62.21
Tangible Book Value	0.1	-99.63	-75.31
Tangible Book Value Per Share	0.01	-58.93	-62.21

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q